Tags : Interim Analysis

Clinical Trials COVID-19

Sinopharm’s COVID-19 Vaccine Demonstrates 79% Efficacy in P-III Study

Shots: The results of an interim analysis of P-III study showed that the safety of the new coronavirus inactivated vaccine after inoculation All patients produced high-titer Abs, the neutralizing Ab positive conversion rate was 99.52% while vaccine efficacy was 79.34% The vaccine has been granted authorization in several countries and has also been rolled out […]Read More